Introducing the
MSS
Microbial Suppression System
Our MSS (Microbial Suppression System) uses EPA registered products that eliminate the presence of bacteria, viruses, fungi, and molds. It creates a submicroscopic molecular coating that inhibits the growth of microorganisms and helps prevent the growth and spread of bacteria. This durable nano-coating can provide lasting antimicrobial protection.
​
Our patented MSS delivery units can quickly and efficiently deliver nano-coating protection for large-scale commercial and industrial applications. It is suitable for use with electronics, keyboards, or touchscreens.
MSS COMPONENTS
MSS Antimicrobial Agent
The EPA registered antimicrobial agents that can be used in conjunction with our system are water-based and odor free.
Antimicrobials agents like ours have proven viability in many areas,
​
[...] antimicrobial polymeric materials provide a valid approach addressing these problems by promoting antimicrobial efficacy and reducing residual toxicity [14,15]. In addition, antimicrobial polymers possess chemical stability and non-volatility, presenting long-term activity [16]. Different from the antimicrobial polymeric materials which are achieved by physically entrapping or coating organic and/or inorganic active agents to the materials during or after processing, polymers containing covalently bonded antimicrobial moieties avoid the problem of the permeation of low-molecular-weight biocides from the polymer matrices. Such antimicrobial polymers promise long-term durability in an environmentally friendly way [...]
MSS Delivery Unit
Our delivery unit applies the MSS antimicrobial nano-coating quickly and effectively. The unit is intrinsically safe and powered by compressed air.
​
​
With this unit, one person can treat thousands of square feet per hour (building floor plan).
HOW THE MSS WORKS
1. Without the MSS nano-coating, microbes settle on surfaces.
​
2. With the MSS nano-coating, microbes are destroyed on contact.
MSS applies an invisible bacteriostatic, fungistatic (mold and mildew), and algaestatic nano-coating.
1.
Disinfecting surfaces will be essential to fighting the pandemic.
​
A new study from the National Institutes of Health, CDC, UCLA, and Princeton University scientists indicate the virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces."
​
2.
The nano-coating disrupts the cell membrane, destroying microbes on contact.
WHY THE MSS WILL MAKE A DIFFERENCE
The MSS is unique in several ways that give it important advantages in the fight against the spread of disease.
IT ADDRESSES A BROAD RANGE OF MICROORGANISMS
​
The MSS is used in conjunction with EPA registered List-N agents that eliminate viruses (including coronaviruses) and EPA registered antimicrobial agents that eliminate bacteria, molds, and fungi.
​
LONG-LASTING PROTECTION
The MSS provides a protective nano-coating capable of use with EPA registered antimicrobial agents that can inhibit the growth of mold to keep indoor and outdoor surfaces mold free for up to 3 months.
​
INDUSTRIAL-SCALE APPLICATION
​
The MSS uses an industrial delivery unit that can efficiently apply the nano-coating over large surfaces for large commercial and industrial applications, such as airports and train stations.
PANDEMIC MITIGATION
AND PREVENTION
​
Mitigating and preventing the spread of infectious disease represents a challenge on a massive scale. The MSS can help by providing antimicrobial protection on an industrial-scale.
​
SAFE FOR HUMANS AND
THE ENVIRONMENT
​
EPA registered antimicrobial agents that can be used in conjunction with our system are water-based and odor free.
OUR TEAM
OUR MISSION | We believe that preventing or mitigating pandemics will require mass-scale protection within society, which NanoVapor’s MSS is equipped to provide by applying its anti-microbial nano-coating over large areas where people frequent in high numbers especially public transportation, schools, government offices, shopping centers, theaters, auditoriums, schools, and churches.
Dr. Maurizio Miglietta
Clinical Medical Director
Dr. Miglietta is a Regional Dean and Professor of Surgery at Touro College of Osteopathic Medicine. He is the former Chief of Acute Care Surgery at the New York-Presbyterian Hospital. Prior to that role at Columbia, he served as Chief of the Division of Trauma & Critical Care at New York University School of Medicine and Director of Trauma and Co-Director of the Surgical Intensive Care Unit at the renowned and historic Bellevue Hospital Trauma Center in New York City.
A graduate of New York College of Osteopathic Medicine/NYIT, Dr. Miglietta completed a General Surgery residency at St. Barnabas in the Bronx, NY. He then completed Trauma and Surgical Critical Care Fellowships at the prestigious R Adams Cowley Shock Trauma Center / University of Maryland. Dr. Miglietta founded and serves as Director of the Homeland Security Mobile Trauma Unit. This unit provided medical care to dignitaries and federal agents in conjunction with the United States Secret Service and Department of State - Diplomatic Security Service. He is an Honorary Police Surgeon providing expert trauma consultation for the New York City Police Department. From 2004 to 2014, he served as the Physician Advisor to the United States Secret Service. He continues to support various federal agencies with medical support.
Dr. Miglietta spearheaded medical education in northern New Jersey by creating 11 residency programs. He is actively involved in educating medical students and residents and served as the Director of Medical Education and Program Director for the Hackensack Meridian General Surgery Residency Program. He has authored and co-authored more than thirty peer-reviewed publications and is dual board certified in Surgery and Critical Care.
As a leader in the profession, Dr. Miglietta serves as Chairman of Surgery at Hudson Regional Hospital as well as New Bridge Medical Center. He practices Robotic & Laparoscopic General Surgery as well as Critical Care. He performed the first robotic general surgery procedures at various New Jersey Hospitals.
Dr. Emmanuel Fombu
Clinical Director of Nanotechnology
Currently serves as a Vice President on the Biopharma team at Locust Walk where he is responsible for driving deal execution. Prior to joining Locust Walk, Dr. Fombu held multiple senior leadership roles in drug development, medical affairs, business development & Licensing and digital innovation at some of the world’s largest pharmaceutical companies including Bayer, Novartis and Johnson and Johnson. He has a track record of successfully launching several drugs in multiple therapeutic areas including but not limited to CNS, Cardiovascular, Immunology, Oncology and Gene Therapy.
Dr. Fambu serves as an external advisory board member at the Massachusetts Institute of Technology’s nanotechnology ‘MIT.nano’ project. As a medical futurist and 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award, Dr. Fombu champions the potential for the internet of things, artificial intelligence and machine learning to revolutionize the healthcare industry.
In addition to his book, The Future of Healthcare: Human and Machine Partnering for Better Outcomes, Dr. Fombu has authored multiple research papers and abstracts in renowned peer reviewed journals. He is a champion and advocate for value-based healthcare, personalized medicine, nanotechnology, blockchain, big data, artificial intelligence, machine learning and digital medicine.
Dr. Fombu completed his clinical training at Emory-Crawford Long Hospital and holds an MBA from both Cornell University’s Johnson School of Business and Queen’s University’s Smith School of Business. He lives in New York City.
Dr. Dorottya Nagy-Szakal
Clinical Director of Microbiology
Dr. Nagy-Szakal received her Doctor of Medicine and Doctor of Philosophy degree’s from Semmelweis University School of Medicine, Budapest, Hungary. Dr. Nagy-Szakal currently holds a Research Assistant Professor position at the Department of Cell Biology, College of Medicine, SUNY Downstate Health Sciences University and the Chief Medical Officer for Biotia Inc., where she is responsible for the clinical molecular diagnostics lab that uses advanced DNA/RNA sequencing techniques and AI-powered reporting for clinical interpretation and pandemic response. She has a strong background as a clinical physician and impressive experience in microbiology, infectious disease and translational medicine as a post-doctoral research scientist at Texas Children’s Hospital and Columbia University’s Center for Infection and Immunity in New York.
Her industry expertise is deep rooted in academic and translational research with 25+ peer reviewed publications and 2 book chapters in the fields of Microbiome, Neuroscience, Clinical Microbiology and Infectious Diseases and Public Health. Dr. Nagy-Szakal has been a UN invited panelist and speaker, President of the New York Hungarian Scientific Society, Director of Community and Partnerships/Co-founder of the Hungarian Idea Exchange.
​
Dr. Russell G. Chew (Chairman & Chief Executive Officer)
Russ Chew previously served as Managing Partner at NEXA Capital Partners, providing Investment Banking and Advisory Services for aerospace and technology companies. Before NEXA, Mr. Chew was President & Chief Operating Officer of JetBlue Airways, served as Chief Operating Officer for the FAA, and was Managing Director of System Operations at American Airlines. In these positions, Mr. Chew managed worldwide operations, maintenance & engineering, strategic planning for operations and technology, technical operations, regulatory requirements, and information technology. Mr. Chew holds a Doctoral Degree from University of Southern California following undergraduate studies at Stanford University.
Richard Staropoli (Chief Operating Officer)
Richard Staropoli spent almost 25 years in the U.S. Government serving as a Special Agent within the US Secret Service, and in the intelligence arena. Staropoli held a number of positions while in the employ of the U.S. Government. After leaving government service, Staropoli was named as the Head of Counter-Party Risk at the Fortress Investment Group, a New York based hedge fund with $80B in AUM. While at Fortress, Staropoli reviewed all deals across Private Equity, Credit & Distressed Debt and Liquid Markets; Staropoli was also responsible for creating and managing the Crypto Currency holdings. In 2016, Staropoli was brought back into Government service after being named by the Administration as the first Presidentially appointed Chief Information Officer at the U.S. Department of Homeland Security. Mr. Staropoli also hold degrees from NYU in mechanical and aerospace engineering.
​
​
Jim Rice (Chief Technology Officer)
Jim Rice is a 33-year veteran of Cabot Corporation, where he last served in Research and Development. Among many management postings, Mr. Rice spent four years in Asia as the Managing Director & CEO of three chemical plants, which he turned around from operations with large losses to profitability. Experienced in management and engineering, Mr. Rice holds a BS in Electrical Engineering from the University of Arkansas and Masters in Electrical Engineering from Washington University, St. Louis.
​
​